Format

Send to

Choose Destination
Aging (Albany NY). 2016 Aug;8(8):1636-49. doi: 10.18632/aging.101019.

Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.

Tseng CH1,2,3.

Author information

1
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
2
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
3
Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Zhunan, Taiwan.

Abstract

This retrospective cohort study investigated whether metformin may reduce gastric cancer risk by using the reimbursement databases of the Taiwan's National Health Insurance. Patients with type 2 diabetes diagnosed during 1999-2005 and newly treated with metformin (n=287971, "ever users of metformin") or other antidiabetic drugs (n=16217, "never users of metformin") were followed until December 31, 2011. The effect of metformin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Results showed that the respective numbers of incident gastric cancer in ever and never users were 759 (0.26%) and 89 (0.55%), with respective incidences of 55.26 and 122.53 per 100,000 person-years. The overall hazard ratio (95% confidence intervals) of 0.448 (0.359-0.558) suggested a significantly lower risk among ever users. In tertile analyses, hazard ratios (95% confidence intervals) for the first (<21.47 months), second (21.47-45.97 months) and third (>45.97 months) tertile of cumulative duration was 0.973 (0.773-1.224), 0.422 (0.331-0.537) and 0.120 (0.090-0.161), respectively, while compared to never users. In conclusion, metformin significantly reduces gastric cancer risk, especially when the cumulative duration is more than approximately 2 years.

KEYWORDS:

Taiwan; diabetes mellitus; gastric cancer; metformin

PMID:
27587088
PMCID:
PMC5032687
DOI:
10.18632/aging.101019
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center